Carregant...
Depot haloperidol decanoate for schizophrenia
BACKGROUND: The mainstay of treatment for schizophrenia is the antipsychotic group of drugs. These are usually given orally but compliance with medication given by this route may be difficult to quantify. Problems with treatment adherence are common. The development of depot injections in the 1960s...
Guardat en:
| Publicat a: | Cochrane Database Syst Rev |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Ltd
1999
|
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7045751/ https://ncbi.nlm.nih.gov/pubmed/10796438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD001361 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|